BRCA2 and breast cancer: Thus relative to BRCA1/BRCA2, germline TP53 mutations are infrequent in French Canadian women with breast cancer, and may be similar (if not lower than) the mutation frequencies observed for specific PALB2 and CHEK2 mutations observed for this population.